It’s a very exciting time for Huntington’s disease (HD) research/clinical trials
because there are many promising clinical trials being conducted the world. 
In the video, (click here), uniQure, a global leader in gene therapy presents the latest update about their study of HD gene therapy AMT-130 in the ongoing HD-GeneTRX trial, and answer community questions. Speakers include Dr. Ed Wild, FRCP, Professor of Neurology at University College London, and Walid Abi-Saab, MD, Chief Medical Officer at uniQure.
Read the complete uniQure Press Release here. “The clinical assessment trends in the ongoing studies of AMT-130 look very promising and continue to show disease stability in Huntington’s disease patients treated with this one-time administered gene therapy, several of whom have now been followed more than two years,” stated Walid Abi-Saab, M.D., chief medical officer of uniQure.
We Can Never Lose HOPE…..
No Comments